Mast cells and basophils are effector cells in the pathophysiology of allergic diseases. Targeted elimination of these cells may be a promising strategy for the treatment of allergic disorders. Our present study aims at targeted delivery of anti-FcεRIα Fab-conjugated celastrol-loaded micelles toward FcεRIα receptors expressed on mast cells and basophils to have enhanced anti-allergic effect. To achieve this aim, we prepared celastrol-loaded (PEO-block-PPO-block-PEO, Pluronic) polymeric nanomicelles using thin-film hydration method. The anti-FcεRIα Fab Fragment was then conjugated to carboxyl groups on drug-loaded micelles via EDC amidation reaction. The anti-FcεRIα Fab-conjugated celastrol-loaded micelles revealed uniform particle size (93.43 ± 12.93 nm) with high loading percentage (21.2 ± 1.5% w/w). The image of micelles showed oval and rod like. The anti-FcεRIα Fab-conjugated micelles demonstrated enhanced cellular uptake and cytotoxity toward target KU812 cells than non-conjugated micelles in vitro. Furthermore, diffusion of the drug into the cells allowed an efficient induction of cell apoptosis. In mouse model of allergic asthma, treatment with anti-FcεRIα Fab-conjugated micelles increased lung accumulation of micelles, and significantly reduced OVA-sIgE, histamine and Th2 cytokines (IL-4, IL-5, TNF-α) levels, eosinophils infiltration and mucus production. In addition, in mouse model of passive cutaneous anaphylaxis, anti-FcεRIα Fab-conjugated celastrol-loaded micelles treatment significantly decreased extravasated evan's in the ear. These results indicate that anti-FcεRIα Fab-conjugated celastrol-loaded micelles can target and selectively kill mast cells and basophils which express FcεRIα, and may be efficient reagents for the treatment of allergic disorders and mast cell related diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1166/jbn.2015.2163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET.
Expert Opin Biol Ther
December 2023
Antibody Discovery & Technology, Sorrento Therapeutics, Inc, San Diego, CA, USA.
Article Synopsis
- - Solid tumors are increasingly common in various age groups and are often linked to high levels of cMET expression, complicating treatment due to the tumor's complexity and interconnected pathways.
- - The study introduces cMET-targeting Fab drug conjugates (FDCs), which combine a Fab fragment with a cytotoxic drug, investigated through both in vitro and in vivo testing.
- - FDCs show significant anti-tumor effectiveness against cMET-overexpressing cancer cells and human gastric tumors in mouse models, suggesting a promising new approach for treating solid tumors.
Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes).
Methods Mol Biol
February 2023
Yunnan Key Laboratory of Screening and Research on Anti-pathogen Plant Resources in Western Yunnan, Dali University, Dali, China.
Immunoliposomes are made by conjugating antibodies or antibody fragments on liposome surfaces. Antibody fragments Fab', single-chain Fv fragments (scFv), or new constructs such as nanobodies are commonly used instead of whole IgGs for reduced risk immunogenicity. Here we described the preparation and characterization of immunoliposome-containing trastuzumab Fabs on the surface.
View Article and Find Full Text PDFDesign and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
Eur J Pharmacol
August 2021
State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China; Shanghai Duomirui Biotechnology Co., Ltd., Shanghai, 201203, China. Electronic address:
Article Synopsis
- Antigen-binding fragments (Fabs) are gaining attention for medical use, but their short half-lives hinder their effectiveness, prompting research into combining them with albumin binding domains (ABD) to enhance their performance.
- The study explored various Fab-ABD fusions targeting tumor necrosis factor-α (TNFα), confirming that these fusions maintained binding activity to TNFα while significantly improving their half-lives and stability in plasma.
- Fab-ABDCon emerged as the most promising candidate due to its improved pharmacokinetics, showing a 22-fold increase in plasma half-life and effective therapeutic results in a murine model for TNFα-induced liver damage.
Co-delivery of siPTPN13 and siNOX4 (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy.
Theranostics
July 2021
Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, 210093, China.
(Myo)fibroblasts are the ultimate effector cells responsible for the production of collagen within alveolar structures, a core phenomenon in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Although (myo)fibroblast-targeted therapy holds great promise for suppressing the progression of IPF, its development is hindered by the limited drug delivery efficacy to (myo)fibroblasts and the vicious circle of (myo)fibroblast activation and evasion of apoptosis. Here, a dual small interfering RNA (siRNA)-loaded delivery system of polymeric micelles is developed to suppress the development of pulmonary fibrosis via a two-arm mechanism.
View Article and Find Full Text PDFDrug-free albumin-triggered sensitization of cancer cells to anticancer drugs.
J Control Release
January 2019
Department of Pharmaceutics and Pharmaceutical Chemistry/Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA; Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA. Electronic address:
Chemosensitization strategies have been used to sensitize cancer cells to conventional drugs, but their utility is often obstructed by additional off-target toxicity, limited access to intracellular targets and heterogeneous tumor pathogenesis. To address these challenges, we rationally developed a drug-free human serum albumin (HSA)-based therapeutic (KH-1) that functions extracellularly and exhibits pleiotropic effect on multiple intracellular signaling pathways. It is a two-step touch-trigger system that consists of a pretargeting anchor on surface receptor CD20 (anti-CD20 Fab' conjugated with a morpholino oligonucleotide 1) and a CD20 clustering actuator (HSA grafted with multiple copies of complementary morpholino oligonucleotide 2).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!